Daily Financial Update
Market Pulse: Crypto storms into a new record as Bitcoin blasts past old ceilings, dragging risk appetite to another level while biotech names snap up gains on fresh wins.
Key Movers: Bitcoin’s whirlwind short squeeze (TheStreet), Nurix Therapeutics’ earnings romp, and Regeneron’s FDA go-ahead are fueling volatility across asset classes.
Macro & Politics: Washington’s steep tariffs on Canadian imports are rattling supply chains and driving investors toward bonded warehouse plays, even as the Supreme Court grants retailers new standing in vaping disputes.
What’s Next: Eyes on any tariff clarifications and FDA updates before markets open—they could fan fresh momentum or trigger a snapback.
Market Commentary
Everyone’s so hyped on crypto’s meteoric surge and biotech breakouts that they’re ignoring the tariff fallout strangling Main Street. Take the century-old Michigan clock maker shuttering operations under Washington’s import levies (NBC News): that’s what a misguided trade policy looks like when theory meets real-world pain. Markets may chase safe-haven plays, but broader small-business casualties are the real red flag—bullshit when they say trade wars only hit the other guy.
Jim Cramer’s “sliding stocks to buy at a bargain” blitz (TheStreet) could be a neat playbook—except we’re staring at a U.S. debt outlook that Fortune says now rivals the student loan crisis. Buying the dip in consumer names makes sense until the debt machinery gobbles up future growth. It’s one hell of a market when bargain hunters lock horns with the ultimate fiscal reckoning.
Here’s the play: stash weight in FDA-friendly biotech stories—Nurix wasn’t the exception, it was the rule, and Kuick Research’s bispecific ADC forecast screams upside. For the crypto crowd, lean into momentum plays like INJ but pare back if ADA’s 23% ramp starts to fizzle (Ambcrypto). Keep chips on both tables, but don’t pretend risk turned docile overnight.
📈 Breaking Financial News
Jim Cramer shares sliding stocks to buy at a bargain
The television personality wants to sound the alarm about all four of these brands.
The 2025 Club World Cup final is here, and the football world comes to a standstill to witness a clash of titans: Chelsea vs PSG This Sunday, July 13, the MetLife Stadium in New Je
Decoding Injective’s breakout: Can INJ bulls target $14 and beyond?
INJ’s breakout triggers bullish momentum, backed by whales, rising funding, and heating futures.
Time runs out for nearly century-old Michigan clock company due to tariffs, other factors
ZEELAND, Mich. (AP) — A Michigan clock company that has helped people keep time for 99 years says it’s going out of business due to tariffs and other economic conditions
Short sellers face market's wrath as $700M gets liquidated in minutes
More than $560 million in crypto positions—mostly shorts—were liquidated in just one hour, with Bitcoin alone accounting for $425 million. A textbook short…
The “Lazy” Way to Make Money in the Market
Discover how millionaire trader Tim Sykes turns his weekends into a cash machine with a single trade on Friday afternoon. Imagine waking up Monday morning thousands of dollars richer… without lifting a finger all weekend!
🔍 Market Analysis & Insights
Why Wall Street is brushing off Trump’s escalating tariff threats
President Donald Trump’s escalating tariff threats have not deterred Wall Street, with the stock market continuing to rise despite trade policy uncertainty.
Bitcoin Bulls In Cloud 9? Analyst Identifies Where Risk Lies
After a near-excellent start to the month of July, Bitcoin has performed even more impressively over the past few days. The premier cryptocurrency, after a brief period of sideways momentum earlier this week, has attained a new all-time-high valuation at a pr…
Bispecific Antibody Drug Conjugates Clinical Trials FDA Approval Market Trends Report
First Bispecific Antibody Drug Conjugates Commercial Approval Expected By 2029 Says Kuick Research First Bispecific Antibody Drug Conjugates Commercial Approval Expected By 2029 Says Kuick Research
Cardano – Here’s why ADA’s 23% rally could call for caution!
ADA might drop soon as it enters a new market phase.
AI ecosystems in full swing at RAISE Summit
I’ve been to several AI-focused conferences since I moved to Europe in 2023. Most of them suffer from trying too hard – driving the hype around AI beyond its current utility. This week’s RAISE Summit in Paris was a refreshing exception. I spoke with several e…
This Tiny AI stock is the “trade of the year”
Huge AI Opportunity: This tiny AI stock could make you 75X richer in 2025!
💰 Investment Opportunities
McKesson Corporation (MCK): If It Was Down, I’d Say “Fill Her Up,” Says Jim Cramer
We recently published Jim Cramer’s Fresh 14 Stocks & Thoughts About Market Performance. McKesson Corporation (NYSE:MCK) is one of the stocks Jim Cramer…
Hate Prime Day? Shop These Small Biz Sales Instead
Feeling anti-Amazon? These small businesses have sales you can shop right now before the week of sales ends.
“I, like many other longtime doves, am joining the hawks, because our nation’s budget math just got a lot more dangerous.”
Processa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio Progress
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) is among the fundamentally strong penny stocks to invest in. Analysts at H.C. Wainwright have reiterated their…
Worst Spate of Downgrades Since 2021 Signals Pain
Credit rating downgrades are becoming more frequent, the latest sign that companies are starting to perform worse and raising fresh questions about whether corporate debt valuations should be as high as they are.
Amazon Spending $10 Billion on THIS…
Jeff Bezos is on a mission to dominate the AI revolution. And he's not afraid to spend BIG. Amazon is pouring billions into a little-known technology most investors are ignoring. But expert Jeff Brown thinks it could be the biggest opportunity of the decade.
